ATE393783T1 - Melanocortinrezeptor-liganden - Google Patents

Melanocortinrezeptor-liganden

Info

Publication number
ATE393783T1
ATE393783T1 AT00919500T AT00919500T ATE393783T1 AT E393783 T1 ATE393783 T1 AT E393783T1 AT 00919500 T AT00919500 T AT 00919500T AT 00919500 T AT00919500 T AT 00919500T AT E393783 T1 ATE393783 T1 AT E393783T1
Authority
AT
Austria
Prior art keywords
receptor ligands
melanocortin receptor
melanocortin
ligands
receptor
Prior art date
Application number
AT00919500T
Other languages
English (en)
Inventor
Adam Mazur
Feng Wang
Russell Sheldon
Frank Ebetino
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of ATE393783T1 publication Critical patent/ATE393783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AT00919500T 1999-03-29 2000-03-21 Melanocortinrezeptor-liganden ATE393783T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12667399P 1999-03-29 1999-03-29

Publications (1)

Publication Number Publication Date
ATE393783T1 true ATE393783T1 (de) 2008-05-15

Family

ID=22426131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919500T ATE393783T1 (de) 1999-03-29 2000-03-21 Melanocortinrezeptor-liganden

Country Status (34)

Country Link
US (2) US6613874B1 (de)
EP (1) EP1165613B1 (de)
JP (1) JP2002542159A (de)
KR (2) KR100519201B1 (de)
CN (1) CN1249086C (de)
AR (1) AR023201A1 (de)
AT (1) ATE393783T1 (de)
AU (1) AU763510B2 (de)
BR (1) BR0009497A (de)
CA (1) CA2368431C (de)
CO (1) CO5170531A1 (de)
CZ (1) CZ20013407A3 (de)
DE (1) DE60038734T2 (de)
DK (1) DK1165613T3 (de)
ES (1) ES2304345T3 (de)
HK (1) HK1044954B (de)
HU (1) HUP0202203A3 (de)
ID (1) ID30262A (de)
IL (1) IL145406A0 (de)
MA (1) MA25403A1 (de)
MX (1) MXPA01009881A (de)
MY (1) MY126585A (de)
NO (1) NO20014568L (de)
NZ (1) NZ514141A (de)
PE (1) PE20001641A1 (de)
PL (1) PL350095A1 (de)
PT (1) PT1165613E (de)
RU (1) RU2213098C2 (de)
SA (1) SA00210192B1 (de)
SK (1) SK13082001A3 (de)
TR (1) TR200102765T2 (de)
TW (1) TWI250990B (de)
WO (1) WO2000058361A1 (de)
ZA (1) ZA200107411B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
AU2001229491A1 (en) * 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
YU15603A (sh) 2000-08-30 2006-05-25 F. Hoffmann-La Roche Ag. Selektivni ciklični peptidi
CZ2003788A3 (cs) * 2000-09-27 2003-08-13 The Procter & Gamble Company Ligandy melanokortinového receptoru
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1644022A1 (de) * 2003-06-19 2006-04-12 Eli Lilly And Company Verwendungen von melanocortin-3-rezeptor (mc3r) peptidagonisten
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
JP2007532471A (ja) * 2003-09-30 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ 新規メラノコルチンレセプターアゴニスト
AU2015201062B2 (en) * 2003-11-05 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
PT1680443E (pt) * 2003-11-05 2013-12-11 Harvard College Péptidos alfa-helicoidais estabilizados e suas utilizações
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
EP1732586A1 (de) * 2004-03-29 2006-12-20 Eli Lilly And Company Verwendungen von melanocortin-3-rezeptor (mc3r) peptidagonisten, die durch kontinuierliche infusion verabreicht werden
WO2006041769A2 (en) * 2004-10-05 2006-04-20 Merck & Co., Inc. Methods for the treatment of substance abuse and addiction
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073772A1 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en) * 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
EP1915168A4 (de) * 2005-07-08 2010-03-31 Ipsen Pharma Liganden von melanocortin-rezeptoren
ES2877349T3 (es) 2005-07-08 2021-11-16 Ipsen Pharma Ligandos de los receptores de la melanocortina
EP1968995A1 (de) * 2005-12-30 2008-09-17 F. Hoffmann-la Roche AG Verfahren zur synthese argininhaltiger peptide
CN101466669B (zh) 2006-06-09 2011-11-30 阿克申制药公司 苯基吡咯氨基胍衍生物
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
JP5656407B2 (ja) * 2006-12-14 2015-01-21 エイルロン セラピューティクス，インコーポレイテッド ビス−スルフヒドリル大環状化系
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2564862B1 (de) 2007-02-23 2017-08-02 Aileron Therapeutics, Inc. Substituierte Aminosäuren zur Herstellung von Triazol enthaltenden macrocyclischen Peptiden
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
RU2450017C2 (ru) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
EP2926827A3 (de) * 2008-02-08 2015-11-04 Aileron Therapeutics, Inc. Therapeutische peptidomimetische Macrocyclen
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
EP2342221B1 (de) 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Verfahren zur herstellung aufgereinigter polypeptidzusammensetzungen
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
RU2012125033A (ru) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
JP2013511554A (ja) 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
BR112012011787B1 (pt) 2009-11-23 2022-03-03 Palatin Technologies, Inc Peptídeo cíclico e composição farmacêutica
CN101824415A (zh) * 2010-03-31 2010-09-08 华东师范大学 黑素皮质1型受体基因的snp及其应用
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2014244232B2 (en) 2013-03-13 2019-05-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
EP3008081B1 (de) 2013-06-14 2017-08-30 President and Fellows of Harvard College Stabilisierte polypeptid-insulinrezeptor-modulatoren
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
CN110681362B (zh) * 2019-09-26 2020-09-11 浙江大学 以羧基和吲哚基为功能基团的混合模式层析介质
US11932628B2 (en) 2021-01-04 2024-03-19 Regents Of The University Of Minnesota Selective small molecule peptidomimetic melanocortin ligands

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462927A (en) 1985-04-30 1995-10-31 The Administrators Of The Tulane Educational Fund Peptides aiding nerve regeneration
EP0292291B1 (de) 1987-05-22 1994-08-10 University Patents, Inc. Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung
JP2795449B2 (ja) 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
ZA908610B (en) 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
ATE140236T1 (de) 1991-02-15 1996-07-15 Takeda Chemical Industries Ltd Endothelin antagoniste
DK0528312T3 (da) 1991-08-13 1997-12-29 Takeda Chemical Industries Ltd Cykliske peptider og anvendelse deraf
EP0552417B1 (de) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Zyklische Peptide und ihre Verwendung
EP0547317A1 (de) 1991-12-19 1993-06-23 Takeda Chemical Industries, Ltd. Endothelin Antagonisten
DE9203901U1 (de) 1992-03-24 1992-07-16 Croon & Lucke Maschinenfabrik Gmbh, 7947 Mengen Gestell zum Lagern von flächigen Werkstücken
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
ES2162822T3 (es) 1992-07-27 2002-01-16 Univ Tulane Utilizacion de octapeptidos para el tratamiento de enfermedades asociadas con el receptor de neuromedina b.
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
EP0714909A1 (de) 1994-12-01 1996-06-05 Takeda Chemical Industries, Ltd. Zusammensetzung zur Vorbeugung und Behandlung von Lungen-Kreislauferkrankungen
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US6136781A (en) 1995-04-28 2000-10-24 Takeda Chemical Industries, Ltd. LH-RH receptor antagonists
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
EP0896544B1 (de) 1996-06-11 2003-02-26 Novartis AG Kombination eines somatostatin analogs und eines rapamycins
CA2258487A1 (en) 1996-06-25 1997-12-31 Nisshin Flour Milling Co., Ltd. Cyclic depsipeptides and drugs containing the same as the active ingredient
EP0815870A3 (de) 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Zubereitung für die Vorbeugung und Behandlung des Schlaganfalls
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
AU5348098A (en) 1996-12-17 1998-07-15 Quadrant Holdings Cambridge Limited Melanocortins
SE9700620D0 (sv) * 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight

Also Published As

Publication number Publication date
CO5170531A1 (es) 2002-06-27
BR0009497A (pt) 2002-01-15
CA2368431C (en) 2006-01-24
CA2368431A1 (en) 2000-10-05
DK1165613T3 (da) 2008-08-25
WO2000058361A1 (en) 2000-10-05
HK1044954B (zh) 2008-11-21
HUP0202203A3 (en) 2003-09-29
HK1044954A1 (en) 2002-11-08
AU4017900A (en) 2000-10-16
TWI250990B (en) 2006-03-11
US6951916B2 (en) 2005-10-04
KR20050009722A (ko) 2005-01-25
MXPA01009881A (es) 2002-05-06
NO20014568D0 (no) 2001-09-20
US20040023859A1 (en) 2004-02-05
ID30262A (id) 2001-11-15
SK13082001A3 (sk) 2002-03-05
PE20001641A1 (es) 2001-02-07
ZA200107411B (en) 2002-05-29
AU763510B2 (en) 2003-07-24
CN1249086C (zh) 2006-04-05
DE60038734T2 (de) 2009-07-02
EP1165613B1 (de) 2008-04-30
HUP0202203A2 (en) 2002-10-28
US6613874B1 (en) 2003-09-02
SA00210192B1 (ar) 2006-06-04
NZ514141A (en) 2004-01-30
TR200102765T2 (tr) 2002-05-21
ES2304345T3 (es) 2008-10-16
MA25403A1 (fr) 2002-04-01
MY126585A (en) 2006-10-31
EP1165613A1 (de) 2002-01-02
DE60038734D1 (de) 2008-06-12
JP2002542159A (ja) 2002-12-10
RU2213098C2 (ru) 2003-09-27
CN1345335A (zh) 2002-04-17
NO20014568L (no) 2001-11-29
AR023201A1 (es) 2002-09-04
IL145406A0 (en) 2002-06-30
CZ20013407A3 (cs) 2002-02-13
PL350095A1 (en) 2002-11-04
KR100558131B1 (ko) 2006-03-10
KR100519201B1 (ko) 2005-10-06
PT1165613E (pt) 2008-07-29
KR20020008143A (ko) 2002-01-29

Similar Documents

Publication Publication Date Title
ATE393783T1 (de) Melanocortinrezeptor-liganden
NO2022060I1 (no) Aflibercept
NO20026280L (no) Melanokortin reseptor-ligander
IL154437A0 (en) Melanocortin receptor ligands
ID26447A (id) Turunan eritropoietin
DE60044873D1 (de) Orientierte biopolymermembrane
ATA51899A (de) Handstempel
DE50007721D1 (de) Trageinrichtung
NO20013954L (no) Understöttelsesanordning
NO20013997D0 (no) Reseptoranalyse
DE59911248D1 (de) Halterung
ID30214A (id) Turunan resorsinol
DE50015643D1 (de) Dekorelement
NO20014961D0 (no) Integrin-reseptor-ligander
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
DE50000236D1 (de) Halterungsanordnung
DE50007184D1 (de) Halterungsanordnung
ATA121799A (de) Ausbeulgerät
DE60020365D1 (de) Säurekatalysierte umsetzungen
ATA107599A (de) Heizwasserbereiter
ATA732000A (de) Kachelofen
AT500658A3 (de) Isolierplatte
NO994224L (no) Underlagsmatte
FI4253U1 (fi) Taka-ajovalorakenne
ES1045226Y (es) Soporte antivibrante mejorado

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165613

Country of ref document: EP

REN Ceased due to non-payment of the annual fee